Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme
Objective: To investigate safety and tolerability of nalmefene for reduction of alcohol consumption in alcohol-dependent patients. Methods: Pooled data from three randomized, placebo-controlled studies (two 6-month; one 12-month) of 18 mg nalmefene (as-needed use) in alcohol-dependent patients looki...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
04 Feb 2015
|
| In: |
Expert opinion on drug safety
Year: 2015, Jahrgang: 14, Heft: 4, Pages: 495-504 |
| ISSN: | 1744-764X |
| DOI: | 10.1517/14740338.2015.1011619 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1517/14740338.2015.1011619 Verlag, Volltext: https://doi.org/10.1517/14740338.2015.1011619 
|
| Verfasserangaben: | Wim van den Brink, John Strang, Antoni Gual, Per Sørensen, Thomas Jon Jensen and Karl Mann |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1565578732 | ||
| 003 | DE-627 | ||
| 005 | 20230427142120.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171121s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1517/14740338.2015.1011619 |2 doi | |
| 035 | |a (DE-627)1565578732 | ||
| 035 | |a (DE-576)495578738 | ||
| 035 | |a (DE-599)BSZ495578738 | ||
| 035 | |a (OCoLC)1340981950 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Brink, Wim van den |e VerfasserIn |0 (DE-588)173248934 |0 (DE-627)698167961 |0 (DE-576)134098145 |4 aut | |
| 245 | 1 | 0 | |a Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence |b results from the Phase III clinical programme |c Wim van den Brink, John Strang, Antoni Gual, Per Sørensen, Thomas Jon Jensen and Karl Mann |
| 264 | 1 | |c 04 Feb 2015 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 21.11.2017 | ||
| 520 | |a Objective: To investigate safety and tolerability of nalmefene for reduction of alcohol consumption in alcohol-dependent patients. Methods: Pooled data from three randomized, placebo-controlled studies (two 6-month; one 12-month) of 18 mg nalmefene (as-needed use) in alcohol-dependent patients looking at the total population (placebo n = 824, nalmefene n = 1123) and patients with high/very high drinking risk levels at screening and randomization (target population: placebo n = 374, nalmefene n = 450). Results: In the study, 62.7% of patients on placebo and 74.7% on nalmefene in the total population had treatment-emergent adverse events (TEAEs). Fourty-seven (5.9%) on placebo and 149 (13.0%) on nalmefene dropped out due to TEAEs. Thirty-five (4.4%) on placebo and 57 (5.0%) on nalmefene had serious adverse events. Tolerability and safety were similar in the target population and total population. Most frequent TEAEs were transient, mainly occurring at treatment initiation. There was no difference in tolerability and safety if nalmefene was taken daily or intermittently; no signal of increased risk of suicide-related behavior with nalmefene. The higher incidence of psychiatric events in the nalmefene group was mainly due to the TEAE of confusional state. Conclusions: Although there was a higher incidence of TEAEs and TEAEs leading to dropout, nalmefene was well-tolerated and no major safety issues were identified. | ||
| 650 | 4 | |a adverse events | |
| 650 | 4 | |a alcohol dependence | |
| 650 | 4 | |a nalmefene | |
| 650 | 4 | |a opioid antagonist | |
| 700 | 1 | |a Mann, Karl |d 1948- |e VerfasserIn |0 (DE-588)120426455 |0 (DE-627)080667872 |0 (DE-576)187088012 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug safety |d Abingdon, Oxon : Routledge, Taylor & Francis, 2002 |g 14(2015), 4, Seite 495-504 |h Online-Ressource |w (DE-627)366928597 |w (DE-600)2114527-1 |w (DE-576)302969721 |x 1744-764X |7 nnas |a Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence results from the Phase III clinical programme |
| 773 | 1 | 8 | |g volume:14 |g year:2015 |g number:4 |g pages:495-504 |g extent:10 |a Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence results from the Phase III clinical programme |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1517/14740338.2015.1011619 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1517/14740338.2015.1011619 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171121 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 120426455 |a Mann, Karl |m 120426455:Mann, Karl |d 60000 |e 60000PM120426455 |k 0/60000/ |p 6 |y j | ||
| 999 | |a KXP-PPN1565578732 |e 2987842384 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"10 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1517/14740338.2015.1011619"],"eki":["1565578732"]},"title":[{"title_sort":"Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence","subtitle":"results from the Phase III clinical programme","title":"Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence"}],"relHost":[{"disp":"Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence results from the Phase III clinical programmeExpert opinion on drug safety","note":["Gesehen am 03.09.15"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Expert opinion on drug safety","title":"Expert opinion on drug safety"}],"language":["eng"],"origin":[{"dateIssuedKey":"2002","publisherPlace":"Abingdon, Oxon ; London [u.a.]","dateIssuedDisp":"2002-","publisher":"Routledge, Taylor & Francis ; Informa Healthcare"}],"recId":"366928597","titleAlt":[{"title":"EODS"}],"id":{"eki":["366928597"],"issn":["1744-764X"],"zdb":["2114527-1"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"text":"14(2015), 4, Seite 495-504","pages":"495-504","issue":"4","year":"2015","extent":"10","volume":"14"},"pubHistory":["1.2002 -"]}],"person":[{"display":"Brink, Wim van den","role":"aut","family":"Brink","given":"Wim van den"},{"role":"aut","display":"Mann, Karl","given":"Karl","family":"Mann"}],"language":["eng"],"origin":[{"dateIssuedDisp":"04 Feb 2015","dateIssuedKey":"2015"}],"name":{"displayForm":["Wim van den Brink, John Strang, Antoni Gual, Per Sørensen, Thomas Jon Jensen and Karl Mann"]},"recId":"1565578732","note":["Gesehen am 21.11.2017"]} | ||
| SRT | |a BRINKWIMVASAFETYANDT0420 | ||